|
US7291615B2
(en)
|
2003-05-01 |
2007-11-06 |
Bristol-Myers Squibb Company |
Cyclic derivatives as modulators of chemokine receptor activity
|
|
EP1715882A4
(en)
*
|
2004-01-16 |
2009-04-08 |
Univ Michigan |
SMAC-PEPTIDOMIMETIKA AND ITS USES
|
|
BRPI0507482A
(pt)
*
|
2004-02-05 |
2007-07-17 |
Novartis Ag |
combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
|
|
AU2005228950B2
(en)
*
|
2004-03-23 |
2012-02-02 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of IAP
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
NZ588799A
(en)
|
2004-07-02 |
2012-06-29 |
Genentech Inc |
Inhibitors of iap
|
|
ES2475207T3
(es)
|
2004-07-15 |
2014-07-10 |
Tetralogic Pharmaceuticals Corporation |
Compuestos de unión a IAP
|
|
DK1836201T4
(da)
*
|
2004-12-20 |
2013-11-11 |
Genentech Inc |
Pyrrolidininhibitorer af IAP.
|
|
PL1851200T3
(pl)
|
2005-02-25 |
2014-06-30 |
Tetralogic Pharm Corp |
Dimeryczne inhibitory IAP
|
|
DE102005017116A1
(de)
*
|
2005-04-13 |
2006-10-26 |
Novartis Ag |
Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
|
|
EP1883627B1
(en)
|
2005-05-18 |
2018-04-18 |
Pharmascience Inc. |
Bir domain binding compounds
|
|
WO2006128455A2
(en)
|
2005-05-25 |
2006-12-07 |
2Curex Aps |
Compounds modifying apoptosis
|
|
US8318717B2
(en)
|
2005-05-25 |
2012-11-27 |
2Curex |
Compounds modifying apoptosis
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
KR20080067357A
(ko)
|
2005-10-25 |
2008-07-18 |
에게라 쎄라퓨틱스 인코포레이티드 |
Iap bir 도메인 결합 화합물
|
|
CA2632807A1
(en)
|
2005-12-19 |
2007-09-20 |
Genentech, Inc. |
Inhibitors of iap
|
|
ES2684120T3
(es)
*
|
2005-12-20 |
2018-10-01 |
Novartis Ag |
Combinación de un inhibidor de IAP y un taxano
|
|
SG170767A1
(en)
*
|
2005-12-23 |
2011-05-30 |
Zealand Pharma As |
Modified lysine-mimetic compounds
|
|
TWI504597B
(zh)
|
2006-03-16 |
2015-10-21 |
Pharmascience Inc |
結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
|
|
WO2007131366A1
(en)
|
2006-05-16 |
2007-11-22 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
EP2049524A2
(en)
|
2006-07-24 |
2009-04-22 |
Tetralogic Pharmaceuticals Corporation |
Iap inhibitors
|
|
US20100113326A1
(en)
*
|
2006-07-24 |
2010-05-06 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
US20100143499A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
WO2008014263A2
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap antagonists
|
|
PE20110218A1
(es)
|
2006-08-02 |
2011-04-01 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
RU2009117701A
(ru)
|
2006-10-12 |
2010-11-20 |
Новартис АГ (CH) |
Производные пирролидина в качестве ингибиторов iap
|
|
PT2089024E
(pt)
|
2006-11-28 |
2011-08-31 |
Novartis Ag |
Combinação de inibidores de iap e inibidores de flt3
|
|
CN101605786A
(zh)
*
|
2006-12-19 |
2009-12-16 |
健泰科生物技术公司 |
细胞凋亡抑制剂的咪唑并吡啶抑制剂
|
|
EP2468724B1
(en)
|
2006-12-21 |
2015-11-18 |
Zealand Pharma A/S |
Synthesis of pyrrolidine compounds
|
|
EP2079309B1
(en)
*
|
2007-04-12 |
2015-11-11 |
Joyant Pharmaceuticals Inc |
SMAC MIMEE DIMERS AND TRIMERS USEFUL AS ANTICANCER AGENTS
|
|
TWI432212B
(zh)
|
2007-04-30 |
2014-04-01 |
Genentech Inc |
Iap抑制劑
|
|
US20110008802A1
(en)
*
|
2007-05-07 |
2011-01-13 |
Tetralogic Pharmaceuticals Corp. |
TNFalpha GENE EXPRESSION AS A BIOMARKER OF SENSITIVITY TO ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS
|
|
AU2009203971A1
(en)
*
|
2008-01-11 |
2009-07-16 |
Genentech, Inc. |
Inhibitors of IAP
|
|
JP2011529962A
(ja)
|
2008-08-02 |
2011-12-15 |
ジェネンテック, インコーポレイテッド |
Iapのインヒビター
|
|
WO2010021934A2
(en)
*
|
2008-08-16 |
2010-02-25 |
Genentech, Inc. |
Azaindole inhibitors of iap
|
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
US20110034469A1
(en)
|
2009-08-04 |
2011-02-10 |
Takeda Pharmaceutical Company Limited |
Heterocyclic Compound
|
|
PE20121132A1
(es)
|
2009-08-12 |
2012-09-04 |
Novartis Ag |
Formulaciones orales solidas y formas cristalinas de un inhibidor de la proteina de apoptosis
|
|
CN102612651A
(zh)
*
|
2009-09-18 |
2012-07-25 |
诺瓦提斯公司 |
Iap抑制剂化合物的生物标志物
|
|
CN102050867A
(zh)
*
|
2009-11-10 |
2011-05-11 |
上海艾力斯医药科技有限公司 |
四肽类似物、制备方法及其应用
|
|
SG182724A1
(en)
|
2010-02-12 |
2012-08-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
RU2666530C2
(ru)
|
2012-01-12 |
2018-09-11 |
Йейл Юниверсити |
Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
|
|
US8859541B2
(en)
*
|
2012-02-27 |
2014-10-14 |
Boehringer Ingelheim International Gmbh |
6-alkynylpyridines
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
US10441654B2
(en)
|
2014-01-24 |
2019-10-15 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
SMC combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
MX390189B
(es)
|
2015-01-20 |
2025-03-20 |
Arvinas Operations Inc |
COMPUESTOS Y METODOS PARA LA DEGRADACION DIRIGIDA DE RECEPTOR DE ANDROGENOs.
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
GB201506872D0
(en)
|
2015-04-22 |
2015-06-03 |
Ge Oil & Gas Uk Ltd |
Novel compounds
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2017011590A1
(en)
*
|
2015-07-13 |
2017-01-19 |
Arvinas, Inc. |
Alanine-based modulators of proteolysis and associated methods of use
|
|
WO2017030814A1
(en)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
RU2018120330A
(ru)
|
2015-11-02 |
2019-12-04 |
Йейл Юниверсити |
Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения
|
|
AU2017367872B2
(en)
|
2016-11-01 |
2022-03-31 |
Arvinas, Inc. |
Tau-protein targeting protacs and associated methods of use
|
|
CN118834201A
(zh)
|
2016-12-01 |
2024-10-25 |
阿尔维纳斯运营股份有限公司 |
作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
|
|
KR102839545B1
(ko)
|
2016-12-23 |
2025-07-29 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
|
WO2018118598A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
KR20190101406A
(ko)
|
2016-12-23 |
2019-08-30 |
아비나스 오퍼레이션스, 인코포레이티드 |
Egfr 단백질분해 표적화 키메라 분자 및 관련 사용 방법
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
CA3049912A1
(en)
|
2017-01-26 |
2018-08-02 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
WO2018202865A1
(en)
|
2017-05-05 |
2018-11-08 |
Zealand Pharma A/S |
Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
|
|
US20210371459A1
(en)
*
|
2017-07-25 |
2021-12-02 |
Hepagene Therapeutics (HK) Limited |
Dimeric peptide inhibitors of apoptosis proteins
|
|
IL272225B2
(en)
*
|
2017-07-27 |
2026-01-01 |
Nat Inst Biotechnology Negev Ltd |
Smac/Diablo inhibitors useful for cancer treatment
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのe3ユビキチンリガーゼ結合活性を有するキメラ(protac)化合物を標的とし、アルファ-シヌクレインタンパク質を標的とするタンパク質分解
|
|
CN114867727B
(zh)
|
2019-07-17 |
2025-02-21 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
IL290789B2
(en)
|
2019-08-26 |
2025-09-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
US12180193B2
(en)
|
2020-08-28 |
2024-12-31 |
Arvinas Operations, Inc. |
Accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
KR20230069144A
(ko)
|
2020-09-14 |
2023-05-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체의 표적화된 분해를 위한 화합물의 결정질 형태
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
AU2024212035A1
(en)
|
2023-01-26 |
2025-08-14 |
Arvinas Operations, Inc. |
Cereblon-based kras degrading protacs ans uses related thereto
|